HON · Honeywell International Inc.
Can Execution Outrun the Multiple?
Executive Thesis
HOLD reflects a high-quality automation franchise whose raised 2026 outlook is substantially embedded in a 27.1x guided EPS multiple. Building Automation, PA&T backlog conversion, Industrial Automation recovery and stranded-cost removal support durable earnings compounding. Yet adjusted free cash flow excludes material separation payments, leverage remains elevated, Quantinuum creates earnings volatility, and PA&T mix is dilutive. Maintain market weight; add below $205 or when evidence shows 2027 earnings and cash conversion exceeding the current valuation burden.
Key Actionable Findings
Click any finding to interrogate with Andy ↗Frequently Asked Questions: HON
What is L2 Capital's investment rating and price target for HON?
L2 Capital currently maintains an institutional rating of HOLD on Honeywell International Inc. (HON) with a 12-month target price of $240.00 (implied return: +5.0%), backed by High conviction.
What is the core investment thesis for HON?
HOLD reflects a high-quality automation franchise whose raised 2026 outlook is substantially embedded in a 27.1x guided EPS multiple. Building Automation, PA&T backlog conversion, Industrial Automation recovery and stranded-cost removal support durable earnings compounding. Yet adjusted free cash flow excludes material separation payments, leverage remains elevated, Quantinuum creates earnings volatility, and PA&T mix is dilutive. Maintain market weight; add below $205 or when evidence shows 2027 earnings and cash conversion exceeding the current valuation burden.
What are HON's latest audited financial fundamentals?
According to audited SEC EDGAR filings, Honeywell International Inc. reported total revenue of $37.44B (-2.7% YoY), Gross Margin of N/A, Free Cash Flow of $5.42B, and Net Debt of $22.45B.
What key risks and catalyst factors should investors monitor for HON?
- Full-year adjusted EPS guidance was raised to $8.40-$8.45, while free cash flow guidance increased to approximately $2.1 billion.
- Third-quarter organic sales grew 7%, segment margin expanded 370 basis points to 21.3%, and backlog reached $18.8 billion.
- At $228.47, the shares trade at approximately 27.1x the midpoint of 2026 adjusted EPS guidance.
- Year-end net debt is targeted near $10 billion, but the September balance sheet still carried $16.6 billion of gross borrowings.